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Abstract
Background: This study was performed to compare the clinical characteristics and antibiotic susceptibilities of
viridans streptococcal bacteremia (VSB) between febrile neutropenic adults and children with hematologic
malignancies.
Methods: The consecutive medical records of neutropenic patients with hematologic malignancies who were
admitted to the Catholic Blood and Marrow Transplantation Center between April 2009 and July 2012, and who
were subsequently diagnosed with VSB were reviewed retrospectively. A comparison was made between the
clinical and laboratory characteristics of adults and pediatric patients and also between patients with cefepime
susceptible or not susceptible VSB.
Results: A total of 202 episodes (141 in adults, 61 in children) of VSB were identified. Among them, 26 (12.9%)
cases had severe complications including four (2.0%) cases of death attributable to VSB. For antibacterial
prophylaxis, most adults received ciprofloxacin (97.1%), but children more frequently received trimethoprim/
sulfamethoxazole (86.9%). Oral mucositis (p = 0.005) and abdominal pain (p = 0.001) were found more frequently in
adults, and cough was found more frequently in children (p = 0.004). The occurrence rates of severe complications
and death attributable to VSB were not significantly different between adults and children. Susceptibility rate to
cefepime was significantly higher in adults than children (85.7% vs. 66.1%, p = 0.002). However, in multivariate
analysis, cefepime susceptibility had no impact on clinical outcome.
Conclusions: There was no significant difference in clinical outcome between adults and children with VSB despite
a difference in cefepime susceptibility. Hence, different antibiotic treatment strategies may not be necessary.
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Background
Bacteremia is identified in 10-27% of febrile neutropenic
patients with hematologic malignancies [1-3], and 18-29%
of the bacteremia is caused by viridans streptococci
[1,4,5]. Although Gram negative bacteria were the most
common isolates to cause bacteremia in febrile neutro-
penic patients in the past [6], viridans streptococci are
currently one of the most common isolates in both adults
and children [1,4,5,7].
Viridans streptococcal bacteremia (VSB) has been
reported to cause severe complications such as shock and
acute respiratory distress syndrome (ARDS) in 18-39% of
infected neutropenic patients and death in up to 20%
[8-10]. A higher occurrence rate of these severe complica-
tions was reported in children compared to adults [11].
Although the Infectious Diseases Society of America
(IDSA) and Korean guidelines state that β-lactam anti-
biotics are adequate for viridans streptococcal infections
[2,12], it is uncertain whether the same practice guide-
lines can be applied to treat infections in adults and
children because of the different complication frequen-
cies [11] and the potentially different antibiotic suscep-
tibilities to viridans streptococci in febrile neutropenic
adults and children with VSB.
We performed this retrospective study to compare
clinical characteristics including the occurrence of severe
complications and antibiotic susceptibilities of viridans
streptococci between febrile neutropenic adults and
children with hematologic malignancies, and to propose




The consecutive medical records of patients diagnosed with
VSB during febrile neutropenia were reviewed retrospec-
tively. The patients were admitted to the Catholic Blood
and Marrow Transplantation (BMT) Center between April
2009 and July 2012, and received conventional chemother-
apy or hematopoietic cell transplantation (HCT) for their
hematologic malignancies. The Catholic BMT Center is
affiliated with Seoul St. Mary’s Hospital in Seoul, Republic
of Korea and is a university-affiliated tertiary center with
about 1,300 beds. There are separate hematology wards
for adults and children, and the adult hematology ward
consists of separate wards for intensive conventional
chemotherapy and HCT patients. The Institutional Re-
view Board (IRB) of Seoul St. Mary’s Hospital approved
this research protocol with a waiver of informed consent
(KC12RISI0607, approved on September 24, 2012).
Patients and data collection
Patients who were younger than 20 years were categorized
as children, and the rest as adults according to the IRB
guideline, and clinical and laboratory characteristics and
antibiotic susceptibilities were compared between the
adults and children. The same clinical and laboratory
characteristics were also compared between patients with
VSB susceptible to cefepime, one of the empirical antibi-
otics used for febrile neutropenic patients, and those with
VSB not susceptible to cefepime. Data gathered on pa-
tients’ demographics and clinical characteristics consisted
of gender, underlying disease with remission status, type
of therapy preceding febrile neutropenia, number of days
from the beginning of respective therapies to the diagnosis
of VSB, use of antibacterial prophylaxis, and occurrence of
oral mucositis, respiratory symptoms, gastrointestinal
symptoms, severe complications and polymicrobial infec-
tion by other bacteria or fungi. Laboratory characteristics
consisted of white blood cell (WBC) count and absolute
neutrophil count (ANC) upon the diagnosis of VSB, the
number of neutropenic days before the diagnosis of VSB,
total number of neutropenic days during the febrile neu-
tropenic episode, and the peak C-reactive protein (CRP)
level within a week after the diagnosis of VSB.
Ceftazidime or cefepime with aminoglycoside, and pipe-
racillin/tazobactam with aminoglycoside were adminis-
tered as initial empirical antibacterial therapy for febrile
neutropenia in adults and children, respectively. After
three to five days of initial antibacterial therapy, an adjust-
ment, if needed, was made according to the Korean guide-
line for febrile neutropenia [12]. Glycopeptides were given
based on the indications recommended by the Korean
guideline [12].
Antibiotic susceptibility test
Blood for culture was sampled using sterile technique
with one set from a peripheral vein and another set from
a central catheter. In adults, 10–15 mL of blood was in-
oculated into each aerobic and anaerobic culture bottle
(BD BACTEC™ Plus Aerobic/F, Lytic/10 Anaerobic/F
Culture Vials, Becton Dickinson, Sparks, MD, USA), and
in children, 1–3 mL of blood was inoculated into a
culture bottle (BD BACTEC™ Peds Plus Culture Vial,
Becton Dickinson, Sparks, MD, USA). The bottles were
immediately transported to the clinical microbiology
laboratory. Automated culture systems were used to de-
tect bacterial growth (BACTEC™ FX, Becton Dickinson,
Sparks, MD, USA) and to identify the exact bacterial
type (VITEK®2, BioMériux, Hazelwood, MO, USA). Anti-
biotic susceptibility tests were performed on a Muller-
Hinton agar plate with 5% sheep blood, according to the
Clinical and Laboratory Standards Institute (CLSI) recom-
mendations [13]. The susceptibilities were determined
by using an E-test for penicillin and cefotaxime, and using
a disk diffusion method for cefepime, erythromycin,
clindamycin, vancomycin, and linezolid. A result of ‘S’ was
considered susceptible, and results of ‘I’ and ‘R’ were
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considered not susceptible. Susceptibility rates to each
antibiotic drug were calculated and compared between
adults and children. Because antibiotic susceptibilities and
clinical characteristics were not significantly different
among viridans streptococcal species [5,9], we did not
identify the different species of viridans streptococci.
Definitions
VSB was defined as growth of viridans streptococci
from at least one peripheral or central blood sample.
Neutropenia was defined as having an ANC lower than
500/μL or an ANC lower than 1,000/μL that was pre-
dicted to be lower than 500/μL within two to three days,
and fever was defined as a body temperature higher
than 38.0°C with a tympanic thermometer or 37.5°C
with an axillary thermometer [12]. Severe complications
included shock, any kind of mechanical ventilator care,
ARDS, and death. Shock was defined as hypotension
(mean arterial pressure less than 60 mmHg in adults,
and systolic blood pressure less than the 5th percentile
to age in children) requiring an intravenous fluid bolus
or inotropic agents to maintain normal blood pressure
[8,14,15], and ARDS was defined as PaO2/FiO2 < 200 in
arterial blood gas analysis of a patient with hypoxia of
SpO2 < 90% and bilateral pulmonary infiltrates on the
chest X-ray [16]. The severe complications were consid-
ered to be attributable to VSB if there was no clinical
improvement after the diagnosis of VSB with severe com-
plications, no other infectious isolates were detected, no
deterioration in underlying malignancy was observed, and
no other clinical diagnoses were made. Death attributable
to VSB was defined as death accompanied by severe com-
plications attributable to VSB within 14 days after the
diagnosis of VSB, and overall death included death from
all causes within a month after the diagnosis of VSB [17].
Statistical analysis
Statistical analysis was performed with SPSS Statistics
17.0 (SPSS Inc., Chicago, IL, USA), and statistical signifi-
cance was defined as a two-sided p < 0.05. In compari-
sons between adults and children and patients with VSB
susceptible and not susceptible to cefepime, a Student’s
t-test was used for numerical variables, and a χ2 test was
used for categorical variables. Multivariate analysis using
multiple logistic regression tests was performed for
statistically significant factors derived from univariate
analysis to determine factors related to the susceptibility
of viridans streptococci to cefepime. The peak CRP level
within a week after the diagnosis of VSB, predicting the
development of severe complications attributable to
VSB, was determined by a receiver operating character-
istic (ROC) curve.
Results
Epidemiology of viridans streptococcal bacteremia in
febrile neutropenic adults and children with hematologic
malignancies
During the study period, there were 2,677 admissions in
1,248 adults and 4,219 admissions in 511 children for
conventional chemotherapy, HCT, or febrile neutro-
penia following chemotherapy. In adults, 745 episodes
of bacteremia in 487 patients and 141 episodes of VSB
in 134 patients were identified, and the incidence of
bacteremia and VSB were 9.17 and 1.74 episodes per
1,000 person-days, respectively. In children, 301 epi-
sodes of bacteremia in 162 patients and 61 episodes of
VSB in 54 patients were identified, and the incidence of
bacteremia and VSB were 6.64 and 1.35 episodes per
1,000 person-days, respectively. Among the total 202
episodes of VSB in adults and children, 42 (20.8%) cases
with severe complications including 14 (6.9%) deaths
were identified, and 26 (12.9%) of them, including four
(2.0%) deaths were attributable to VSB. The other cases
leading to mortality were due to uncontrolled under-
lying hematologic malignancies. Multiple episodes of
VSB were diagnosed in 11 patients. Eight patients (five
adults and three children) each experienced two episodes,
and three patients (one adult and two children) each expe-
rienced three episodes of VSB. Each episode was diag-
nosed during separate admissions. None of the patients
experienced multiple episodes of severe complications.
Comparison of clinical and laboratory characteristics
between adults and children
Among the total 202 cases of VSB, 108 (53.5%) cases were
male, and 147 (72.8%) cases suffered from acute myeloid
leukemia (AML). VSB occurred a median of 12 days (inter
quartile range, IQR: 10–14) after the preceding therapy.
Conventional chemotherapy and HCT accounted for
95.0% and 5.0% of the preceding therapy, respectively.
Diarrhea (60/202, 29.7%) was the most common symptom
accompanying fever, and was followed by oral mucositis
(41/202, 20.3%) and abdominal pain (38/202, 18.8%).
More children were male compared to the adult group
(p = 0.010, Table 1). AML accounted for about 70% of
the underlying diseases in both adults and children, and
the distribution of underlying diseases was not signifi-
cantly different between the two groups (Table 1). All
children with VSB had been treated with conventional
chemotherapy, whilst 92.9% of adults had been treated
with conventional chemotherapy, and 7.1% with HCT.
The type of preceding therapy was not significantly dif-
ferent between the two groups (Table 1). The median
number of days from the beginning of the preceding
therapy to the diagnosis of VSB was 12 days (IQR: 10–
13) in adults and 13 days (IQR: 12–14) in children, and
this difference was statistically significant (p < 0.001,
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Table 1 Comparison between adults and children with viridans streptococcal bacteremia during febrile neutropenia
Factor Adults (≥ 20 years old) (n=141) Children (< 20 years old) (n=61) p-value
Age (years) 44 (36-54) 9 (3-15)
Gender (male) 67 (47.5) 41 (67.2) 0.010
Underlying disease 0.215
Acute myeloid leukemia 103 (73.1) 44 (72.1)
Acute lymphoblastic leukemia 23 (16.3) 13 (21.3)
Other leukemias 4 (2.8) 3 (4.9)
Non-Hodgkin lymphoma 8 (5.7) 1 (1.6)
Multiple myeloma 3 (2.1) 0 (0.0)
Complete remission status 84 (59.6) 40 (65.6) 0.421
Preceding therapy 0.103
Conventional chemotherapy 131 (92.9) 61 (100.0)
Hematopoietic cell transplantation
Autologous 8 (5.7) 0 (0.0)
Allogeneic 2 (1.4) 0 (0.0)
Duration after the preceding therapy (days) 12 (10-13) 13 (12-14) <0.001
Antibacterial prophylaxis* < 0.001
None 4 (2.9) 1 (1.6)
Trimethoprim/sulfamethoxazole 0 (0) 53 (86.9)
Ciprofloxacin 134 (97.1) 7 (11.5)
Accompanying symptoms
Oral mucositis 36 (25.5) 5 (8.2) 0.005
Cough 9 (6.4) 12 (19.7) 0.004
Sputum 5 (3.5) 4 (6.6) 0.458
Rhinorrhea 1 (0.7) 0 (0.0) 1.000
Diarrhea 46 (32.6) 14 (23.0) 0.167
Abdominal pain 35 (24.8) 3 (4.9) 0.001
Polymicrobial infection
Other bacterial infection 18 (12.8) 4 (6.6) 0.193
Fungal infection 16 (11.3) 2 (3.3) 0.065
Complications attributable to VSB 22 (15.6) 4 (6.6) 0.078
Ventilator care 5 (3.5) 3 (4.9) 0.700
Acute respiratory distress syndrome 4 (2.8) 2 (3.3) 1.000
Shock 22 (15.6) 4 (76.6) 0.078
Death 3 (2.1) 1 (1.6) 1.000
Overall death 12 (8.5) 2 (3.3) 0.236
Laboratory findings
White blood cell count (/μL) 50 (20-160) 60 (30-135) 0.127
Absolute neutrophil count (/μL) 0 (0-0) 0 (0-0) 0.228
Duration of neutropenia before the diagnosis of VSB (days) 6 (4-7) 6 (4-8) 0.138
Total duration of neutropenia (days) 17 (12-24) 15 (11-22) 0.823
Peak C-reactive protein level (mg/dL) 19.6 (13.2-26.5) 18.6 (9.7-25.5) 0.157
Data are median (inter quartile range) or No. (%) of cases.
VSB viridans streptococcal bacteremia.
*Antibacterial prophylaxis was evaluated in 199 patients (138 adults, 61 children) except 3 adults who had been undergoing ceftazidime treatment.
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Table 1). Antibacterial prophylaxis was administered to
194 (96.0%) patients; 141 (69.8%) patients received
ciprofloxacin (500 mg twice a day), and 53 (26.2%) pa-
tients received trimethoprim/sulfamethoxazole (TMP/
SMX, trimethoprim 150 mg/m2 once a day, three times
a week). Five (2.5%) patients did not receive any antibac-
terial prophylaxis, and the other three (1.5%) patients
experienced VSB during antibiotic treatment with
ceftazidime given due to preceding febrile neutropenia.
Adults received ciprofloxacin more frequently (97.1%),
and children received TMP/SMX more frequently
(86.9%, Table 1). This difference in antibacterial prophy-
laxis occurred because fluoroquinolones are not recom-
mended to children aged less than 18 years in Korea due
to the risk of skeletal abnormalities. The seven patients
in the pediatric group who received ciprofloxacin
prophylaxis were older than 18 years. Among the symp-
toms accompanying VSB, oral mucositis (p = 0.005) and
abdominal pain (p = 0.001) were more common in
adults, and cough was more common in children (p =
0.004, Table 1). The occurrence rates of severe complica-
tions attributable to VSB, overall mortality, and mortality
attributable to VSB were not significantly different be-
tween adults and children (Table 1). CRP levels were
measured a median of three times (IQR: 3–3) within the
first week after the diagnosis of VSB, and the peak CRP
levels within a week were detected a median of four days
(IQR: 3–5) after the diagnosis of VSB. The frequency of
measuring CRP levels and the time of the peak CRP
levels were not significantly different between adults and
children. There was no significant difference in labora-
tory results between adults and children (Table 1).
Comparison of antibiotic susceptibilities between adults
and children
Antibiotic susceptibility was assessed in 201/202 (99.5%)
of bacterial isolates, that is, all the isolates except for
one from an adult patient (Table 2). In adults, the sus-
ceptibility rate to each antibiotic was: penicillin 57/140
(40.7%), cefotaxime 127/140 (90.7%), cefepime 120/140
(85.7%), vancomycin 140/140 (100%), linezolid 140/140
(100%), clindamycin 121/140 (86.4%), and erythromycin
78/140 (55.7%). In children, the susceptibility rates were:
penicillin 22/61 (36.1%), cefotaxime 39/60 (65.0%),
cefepime 39/59 (66.1%), vancomycin 61/61 (100%),
linezolid 60/61 (98.4%), clindamycin 51/61 (83.6%), and
erythromycin 21/61 (34.4%). The susceptibility rates to
cefotaxime, cefepime, and erythromycin were signifi-
cantly higher in adults than in children (Table 2).
Comparison between patients with severe complications
attributable to viridans streptococcal bacteremia and
those without severe complications
The median of peak CRP levels within a week after the
diagnosis of VSB was 27.2 mg/dL (IQR: 21.4-33.7) in pa-
tients with severe complications attributable to VSB and
17.8 mg/dL (IQR: 11.8-25.5) in those without severe
complications. These were significantly different (p <
0.001). Peak CRP levels were detected a median of four
days (IQR: 3–5) after the diagnosis of VSB in the two
groups without a significant difference. The cut-off value
of the peak CRP level predicting the development of se-
vere complications attributable to VSB was determined
using an ROC curve as 21.0 mg/dL (Area under the
curve = 0.772) with sensitivity, specificity, positive pre-
dictive value, and negative predictive value of 77%, 62%,
23%, and 95%, respectively. There were no other signifi-
cant differences in clinical and laboratory characteristics
between the two groups. The antibiotic susceptibility
rate of each antibiotic drug was not significantly differ-
ent between the two patient groups (Table 3).
Comparison between patients with viridans streptococcal
bacteremia susceptible to cefepime and not susceptible
to cefepime
Susceptibility tests to cefepime were conducted in 199
isolates, and 159 (79.9%) isolates were susceptible to
cefepime (Table 4). In univariate analysis, patients with
Table 2 Comparison of antibiotic susceptibility rates between adults and children
Antibiotics All patients* (n=201) Adults (≥ 20 years old) (n=140) Children (< 20 years old) (n=61) p-value
Penicillin 79/201 (39.3) 57/140 (40.7) 22/61 (36.1) 0.535
Cefotaxime† 166/200 (83.0) 127/140 (90.7) 39/60 (65.0) < 0.001
Cefepime‡ 159/199 (79.9) 120/140 (85.7) 39/59 (66.1) 0.002
Vancomycin 201/201 (100.0) 140/140 (100.0) 61/61 (100.0) NA
Linezolid 200/201 (99.5) 140/140 (100.0) 60/61 (98.4) 0.303
Clindamycin 172/201 (85.6) 121/140 (86.4) 51/61 (83.6) 0.601
Erythromycin 99/201 (49.3) 78/140 (55.7) 21/61 (34.4) 0.006
Data are No. (%) of cases.
NA not available.
*Antibiotic susceptibility tests were performed in 201 patients (140 adults, 61 children).
†Antibiotic susceptibility tests were performed in 200 patients (140 adults, 60 children).
‡Antibiotic susceptibility tests were performed in 199 patients (140 adults, 59 children).
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VSB susceptible to cefepime were older (p = 0.005),
more likely to be in complete remission status (p =
0.037), more likely to have received ciprofloxacin
prophylaxis (p < 0.001), and had a longer duration of
neutropenia before the diagnosis of VSB (p = 0.021) than
patients with VSB not susceptible to cefepime (Table 4).
However, there was no significant factor related to
cefepime susceptibility in multivariate analysis (Table 5).
Medical records on the complete course of chemo-
therapy and antibacterial therapy for febrile neutropenia
with antibiotics which have anti-pseudomonal effect
since the diagnosis of hematologic malignancies were
reviewed in 166 cases (124 adults, 42 children). Of the
remaining cases, medical records of 16 patients who
had been referred from other hospitals were not
completely reviewed, and 17 patients who had been
newly diagnosed with hematologic malignancies were
excluded because they had no previous history of anti-
bacterial therapy for febrile neutropenia. The interval
from the diagnosis of hematologic malignancy to the
diagnosis of VSB was a median of three months (IQR:
2–7). Among the 166 patients, 137 patients with VSB
susceptible to cefepime and 29 patients with VSB not
susceptible to cefepime received a median of one course
(IQR: 1–2) and a median of two courses (IQR: 1–2) of
antibacterial therapy for febrile neutropenia, respect-
ively. The number of preceding antibacterial therapies
for febrile neutropenia was not significantly different
between patients with VSB susceptible and not suscep-
tible to cefepime (Table 4).
Discussion
We investigated the clinical and laboratory characteristics
of VSB in febrile neutropenic patients with hematologic
malignancies and the antibiotic susceptibilities of the
viridans streptococci. The data were compared between
adults and children and also in patients with VSB suscep-
tible and not susceptible to cefepime.
VSB occurred most commonly in AML patients
(72.7%), 12 days (IQR: 10–14) after the beginning of
consolidation chemotherapy (57.9%), and six days (IQR:
4–8) after the onset of neutropenia. This pattern of VSB
occurrence was consistent with previous reports [18].
While oral mucositis, a risk factor for VSB, occurred in
roughly 60% of patients with VSB in previous reports
[9,19], it occurred at a lower rate of 20.3% in this study.
On the other hand, gastrointestinal symptoms were
common in all patient groups, and cough was common
in children. Considering that viridans streptococci are
normal flora of the gastrointestinal and upper respira-
tory tracts as well as oral mucosa [20,21], and that
mucosal damage can occur at these sites following
chemotherapy or HCT, this was a predictable result.
Since young children often cannot adequately complain of
their oral and abdominal pain, and their parents or medical
personnel might easily recognize objective symptoms, such
as diarrhea and cough, the reported incidence of oral
mucositis and abdominal pain might be lower in children
than in adults. Other clinical and laboratory characteristics
were not significantly different between adults and children,
and the aforementioned symptoms occurred in less than
one-third of patients. Therefore, we concluded that there
were no distinctive characteristics to distinguish between
VSB in adults and children.
The 12.9% occurrence rate of severe complications at-
tributable to VSB was lower than that of previous reports,
which showed an occurrence rate of 18-39%, and the 2.0%
mortality attributable to VSB in this study was also lower
than that of previous reports, which showed mortality up
to 20% [8-10]. Although Martino et al. [11] reported a
higher occurrence rate of severe complications and death
due to VSB in children than in adults, the occurrence rate
of severe complications and death attributable to VSB and
overall mortality were not significantly different between
adults and children in the present study. Previous re-
searchers did not find significant factors related to a worse
Table 3 Antibiotic susceptibility rates according to the occurrence of severe complications attributable to viridans
streptococcal bacteremia
Antibiotics All patients* (n=201) Without complications (n=175) With complications (n=26) p-value
Penicillin 79/201 (39.3) 70/175 (40.0) 9/26 (34.6) 0.600
Cefotaxime† 166/200 (83.0) 142/174 (81.6) 24/26 (92.3) 0.263
Cefepime‡ 159/199 (79.9) 136/173 (78.6) 23/26 (88.5) 0.243
Vancomycin 201/201 (100.0) 175/175 (100.0) 26/26 (100.0) NA
Linezolid 200/201 (99.5) 174/175 (99.4) 26/26 (100.0) 1.000
Clindamycin 172/201 (85.6) 151/175 (86.3) 21/26 (80.8) 0.548
Erythromycin 99/201 (49.3) 86/175 (49.1) 13/26 (50.0) 0.935
Data are No. (%) of cases.
NA not available.
*Antibiotic susceptibility tests were performed in 201 patients (175 without severe complications, 26 with severe complications).
†Antibiotic susceptibility tests were performed in 200 patients (174 without severe complications, 26 with severe complications).
‡Antibiotic susceptibility tests were performed in 199 patients (173 without severe complications, 26 with severe complications).
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Table 4 Comparison between patients with viridans streptococcal bacteremia susceptible to cefepime and those not
susceptible to cefepime
Factor Susceptible to cefepime (n=159) Not susceptible to cefepime (n=40) p-value
Age (years) 38 (20-51) 17 (2-51) 0.013
Gender (male) 89 (56.0) 19 (47.5) 0.456
Underlying disease 0.320
Acute myeloid leukemia 117 (73.6) 28 (70.0)
Acute lymphoblastic leukemia 26 (16.4) 9 (22.5)
Other leukemias 6 (3.1) 1 (2.5)
Non-Hodgkin lymphoma 8 (5.0) 1 (2.5)
Multiple myeloma 2 (1.3) 1 (2.5)
Complete remission status 104 (65.4) 19 (47.5) 0.037
Preceding therapy 0.732
Conventional chemotherapy 151 (95.0) 38 (95.0)
Hematopoietic cell transplantation
Autologous 6 (3.8) 2 (5.0)
Allogeneic 2 (1.3) 0 (0.0)
Duration after the preceding therapy (days) 12 (10-14) 13 (10-13) 0.568
Antibacterial prophylaxis* <0.001
None 4 (2.5) 1 (2.7)
Trimethoprim/sulfamethoxazole 31 (19.5) 20 (54.1)
Ciprofloxacin 124 (78.0) 16 (43.2)
Probability of antibacterial therapy after chemotherapy† (%) 84.0 ± 29.6 81.8 ± 32.0 0.864
Previous antibacterial therapy for febrile neutropenia† (times) 1 (1-2) 2 (1-2) 0.284
Accompanying symptoms
Oral mucositis 35 (22.0) 6 (15.0) 0.327
Cough 18 (11.3) 2 (5.0) 0.377
Sputum 6 (3.8) 3 (7.5) 0.388
Rhinorrhea 1 (0.6) 0 (0.0) 1.000
Diarrhea 50 (31.4) 8 (20.0) 0.154
Abdominal pain 34 (21.4) 4 (10.0) 0.102
Polymicrobial infection
Other bacterial infection 17 (10.7) 5 (12.5) 0.779
Fungal infection 16 (10.1) 2 (5.0) 0.537
Complications attributable to VSB 23 (14.5) 3 (7.5) 0.243
Ventilator care 8 (5.0) 0 (0.0) 0.362
Acute respiratory distress syndrome 6 (3.8) 0 (0.0) 0.602
Shock 23 (14.5) 3 (7.5) 0.243
Death 4 (2.5) 0 (0.0) 0.585
Overall death 13 (8.2) 1 (2.5) 0.309
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prognosis in children, and there have been few studies
comparing the clinical characteristics and prognoses
between adults and children. Comparisons between adults
and pediatric patients with severe complications attribut-
able to VSB showed that children more commonly
complained of cough and had a longer duration between
the beginning of the preceding therapy and the diagnosis
of VSB, similar to the comparison between all adults and
children with VSB. When comparing patients with severe
complications attributable to VSB and those without
severe complications in this study, there was no significant
difference except for the peak CRP level within a week
after the diagnosis of VSB. This had a low positive predict-
ive value of 23% for the occurrence of severe complications.
Thus, we were also unable to identify a definite factor that
could help anticipate severe complications in VSB.
Antibiotic susceptibility rates to cefotaxime, cefepime,
and erythromycin were lower in children than in adults.
Although we performed both univariate and multivariate
analyses to determine risk factors for decreased suscepti-
bility to cefepime, no significant factors were found.
Recurrent antibiotic use may be related to the increase
in antibiotic resistance [22,23]; however, there was no
difference between patients with VSB susceptible and
not susceptible to cefepime in the number of antibacter-
ial therapies for febrile neutropenia after previous
conventional chemotherapy or HCT. The fact that the
first-line antibiotic agent for patients with hematologic
malignancies was cefepime or ceftazidime in most adults
and piperacillin/tazobactam for almost all children in
our hospital also supports the finding that previous
antibiotic use is not related to decreased susceptibility to
cefepime. We also analyzed the effect of prophylactic
antibiotics on susceptibility to cefepime since ciprofloxa-
cin, principally given to adults, has a limited effect on
Gram positive bacteria [24,25], while TMP/SMX, princi-
pally given to children, has a satisfactory effect [25,26].
The effect of prophylactic antibiotics on decreased sus-
ceptibility to cefepime may be small since antibacterial
prophylaxis has been reported to be unrelated to in-
creased antibiotic resistance in a meta-analysis [27], and
since patients in the present study received ciprofloxacin
or TMP/SMX rather than β-lactam antibiotics and anti-
bacterial prophylaxis with these antibiotics is not known
to trigger antibiotic resistance in viridans streptococci
[22,28,29]. Nevertheless, prophylactic antibiotic effects
on decreased susceptibility to cefepime should not be
ignored. Viridans streptococci can acquire β-lactam re-
sistance through transfer of the mutated penicillin bind-
ing protein gene from Streptococcus pneumoniae [30,31],
and it has been reported that the resistance of S.
pneumoniae to β-lactam antibiotics after TMP/SMX
prophylaxis in human immunodeficiency virus-infected
patients can increase by a factor of 1.71 [32]. However,
Table 4 Comparison between patients with viridans streptococcal bacteremia susceptible to cefepime and those not
susceptible to cefepime (Continued)
Laboratory findings
White blood cell count (/μL) 60 (20-160) 40 (20-118) 0.194
Absolute neutrophil count (/μL) 0 (0-0) 0 (0-0) 0.915
Duration of neutropenia before the diagnosis of VSB (days) 5 (4-7) 7 (5-11) 0.021
Total duration of neutropenia (days) 16 (12-23) 20 (12-24) 0.094
Peak C-reactive protein level (mg/dL) 19.6 (13.1-26.1) 17.1 (9.3-28.1) 0.397
Data are median (inter quartile range), mean ± SD, or No. (%) of cases.
VSB viridans streptococcal bacteremia.
*Antibacterial prophylaxis was evaluated in 196 patients (159 with viridans streptococcal bacteremia susceptible to cefepime, 37 with viridans streptococcal
bacteremia not susceptible to cefepime) except 3 patients who had been undergoing ceftazidime treatment and 3 patients in whom cefepime susceptibility tests
were not done.
†Information on previous chemotherapies and antibacterial therapies was completely reviewed in 166 patients (137 with viridans streptococcal bacteremia
susceptible to cefepime, 29 with viridans streptococcal bacteremia not susceptible to cefepime).
Table 5 Multivariate analysis for risk factors for non-susceptibility to cefepime
Factor Odds ratio 95% confidence interval p-value
Age 1.001 0.967 – 1.037 0.936
Complete remission status 0.674 0.285 – 1.595 0.369
Antibacterial prophylaxis
None 0.074
Trimethoprim/sulfamethoxazole 2.010 0.152 – 26.588 0.596
Ciprofloxacin 0.396 0.041 – 3.872 0.426
Duration of neutropenia before the diagnosis of VSB 1.063 0.988 – 1.144 0.101
VSB viridans streptococcal bacteremia.
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resistance to penicillin of S. pneumoniae was 0.3% in
nonmeningeal isolates and 83.3% in meningeal isolates,
and ceftriaxone resistance was 1.9% in nonmeningeal
isolates and 0% in meningeal isolates from 2008 to 2009
in the Republic of Korea [33]. The exact effect of
prophylactic antibiotics on the development of antibiotic
resistance remains controversial [2], and the type of anti-
biotics, duration of prophylaxis, bacterial species, and
host factors may influence the development of antibiotic
resistance [22,34].
In this study, there were no definite differences in
clinical and laboratory characteristics, mortality, or
occurrence of severe complications between febrile
neutropenic adults and children with VSB, despite a
significant difference in antibiotic susceptibility to
cefepime between the two groups. Antibiotic suscepti-
bilities were not significantly related to the development
of severe complications. Thus, our study results show
that different antibiotic treatment strategies for adults
and children with VSB are not necessary. The lower
susceptibility rate of 66.1% to cefepime in children may
indicate the need for initial glycopeptide therapy in
febrile neutropenic children. However, bacteremia is di-
agnosed in 10-25% of febrile neutropenic children [1-3],
and 20-30% of the bacteremia is caused by viridans
streptococci [1,4,5]. In addition, since severe compli-
cations occurred in 6.6% of the patients with VSB
according to our results, we estimate that the incidence
of severe complications of VSB in febrile neutropenic
children is 0.5%. Therefore, considering that antibiotic
susceptibility is not significantly related to the prognosis
of VSB in febrile neutropenia [5,9], universal initial gly-
copeptide therapy targeting only 0.5% of febrile neutro-
penic children with hematologic malignancies should
not be considered. Instead, we should consider glyco-
peptide therapy if antibiotic susceptibility tests revealed
that the isolated viridans streptococci were not suscep-
tible to antibiotics being administered to the patient and
susceptible to glycopeptides.
This study has several limitations including its retro-
spective nature. We tried to eliminate selection bias by
including all consecutive hematologic malignancy pa-
tients with VSB who were treated in the same hospital
environment. Also, there were some limitations in our
tests for antibiotic susceptibility. The results of the
E-test and disk diffusion method for antibiotic susceptibi-
lity in this study may be different from results of broth
microdilution methods. Additionally the clinical la-
boratory of our hospital did not perform piperacillin/
tazobactam susceptibility test for viridans streptococci;
thus, we assumed that cefepime susceptibility was simi-
lar to piperacillin/tazobactam susceptibility. This as-
sumption may not be applicable to clinical settings.
Lastly, past histories of antibacterial therapy for febrile
neutropenia were reviewed to evaluate its effect on the
differences in antibiotic susceptibility; however, infor-
mation from 35 patients was missing. Although we as-
sumed that previous antibacterial therapies should not
influence β-lactam susceptibilities, the relationship
should be further investigated.
Conclusions
In this study, no definite differences in clinical and labora-
tory characteristics or prognosis were found between
febrile neutropenic adults and children with VSB. While
susceptibility to cefepime was lower in children, there
were no differences in clinical characteristics or prognosis
between patients with VSB susceptible and not susceptible
to cefepime. Therefore, this study showed that different
antibiotic treatment strategies for adults and children with
VSB are not necessary, and also confirmed that current
IDSA and Korean guidelines for febrile neutropenic pa-
tients may be applied to both febrile neutropenic children
and adults with VSB. Further studies on the cause and
clinical significance of the difference in antibiotic suscepti-
bility rates between adults and children are needed.
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